Gene-based cancer vaccines: An ex vivo approach

Leukemia

Volumn 15, Issue 4, 2001, Pages 545-558

  Van Tendeloo, V F I ^a,b   Van Broeckhoven, C ^b   Berneman, Z N ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Adenoviral vectors; Cancer immunotherapy; Cancer vaccines; Cross priming; Cytotoxic T lymphocytes; Danger theory; Dendritic cells; Gene therapy; Gene transfer; Immune tolerance; Lentiviral vectors; Nonviral gene transfer; Retroviral vectors; Suicide genes; T bodies; Tumor immunology; Tumor rejection antigens; Tumor vaccines; Tumor associated antigens

Indexed keywords

ADJUVANT; BCG VACCINE; CANCER VACCINE; CORYNEBACTERIUM PARVUM VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CANCER RESEARCH; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; DRUG RESEARCH; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TECHNOLOGY; TUMOR CELL; VACCINATION; VIRUS GENE;

EID: 0035060334     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402069     Document Type: Review

References (196)

1. The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes
2. The concept of immunological surveillance
3. + T and NK cells
4. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
5. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells
6. Melanoma cell expression of Fas(Apo-1/CD951 ligand: Implications for tumor immune escape
7. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: How do I lose thee? Let me count the ways'
8. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
9. Developing recombinant and synthetic vaccines for the treatment of melanoma
10. A new era for cancer immunotherapy based on the genes that encode cancer antigens
11. Ex-vivo gene therapy using cytokine transduced tumor vaccines: Molecular and clinical pharmacology
12. Dendritic cells: Development, function and potential use for cancer immunotherapy
13. Gene therapy for cancer
14. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma
15. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
16. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans
17. Genetically marking human cells - Results of the first clinical gene transfer studies
18. Toxicity and immunomodulatory effects or interleukin-2 after autologous bone marrow transplantation for hematologic malignancies
19. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth
20. The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors
21. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
22. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
23. Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy
24. Transfer or the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation
25. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: A phase I II study
26. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
27. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus leukemia: Clinical follow-up and improved new vectors
28. Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation?
29. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis
30. The makings of a tumor rejection antigen
31. Human tumor antigens recognized by T lymphocytes
32. Cancer vaccines based on the identification of genes encoding cancer regression antigens
33. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines
34. Treatment of of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
35. Murine interleukin-4 displays potent anti-tumor activity in vivo
36. Local administration or cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice
37. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
38. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
39. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
40. Induction in a murine tumor or immunogenic tumor variants by transfection with a foreign gene
41. Induction of anti-self-immunity to cure cancer
42. Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld)
43. Generation of therapeutic T-lymophocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene
44. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes
45. Cytokines and cancer: Experimental systems
46. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1
47. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML
48. Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines
49. Gene therapy with 87.1 and GM-CSF vaccines in a murine AML model
50. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
51. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
52. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte macrophage colony-stimulating factor transfer
53. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
54. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants
55. Immunotherapy via gene therapy: Comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes
56. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte macrophage colony-stimulating factor gene transfer
57. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
58. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines
59. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity
60. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
61. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
62. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A phase I study
63. A universal granulocyte macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines
64. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal
65. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
66. Enhanced tumor protection by granulocyte macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
67. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
68. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant
69. Gene therapy for cancer: What have we done and where are we going?
70. Long-term persistence human bone marrow stromal cells transduced with factor VIII retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice
71. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny
72. Large-scale processing of recombinant retroviruses for gene therapy
73. Establishment of an optimised gene transfer prorocol for human primary T lymphocytes according to clinical requirements
74. Design of 5′ untranslated sequences in retroviral vectors developed for medical use
75. Gene therapy for hemophilia: Hopes and hurdles
76. Improvement of retroviral packaging cell lines by introducing the polyomavirus early region
77. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells
78. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors
79. Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells
80. Development and application of adenoviral vectors for gene therapy of cancer
81. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
82. Gene therapy death prompts review of adenovirus vector
83. Virus treatment questioned after gene therapy death
84. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
85. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
86. Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system
87. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): Delivery to acute myeloid leukemic blasts using adeno-associated virus
88. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance Y-cell immunity and antitumor responses
89. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
90. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines
91. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
92. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors
93. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses
94. Development of a self-inactivating lentivirus vector
95. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
96. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
97. On the strategy of using nonviral carriers in cancer gene therapy
98. Synthetic DNA delivery systems
99. Molecular conjugates: A targeted gene delivery vector for molecular medicine
100. High-efficiency gene transfer mediated by adeno-virus-polvlysine-DNA complexes
101. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection
102. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation
103. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
104. Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice?
105. Interleukin-7/B7. 1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors
106. Tumor-induced immuno-suppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
107. Gene-based strategies for the immunotherapy of cancer
108. Cancer gene and immunotherapy: Recent developments
109. Tolerance, danger, and the extended family
110. Ablation of 'tolerance' and induction of diabetes bs virus infection in viral antigen transgenic mice
111. T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E
112. Death, destruction, danger and dendritic cells (news)
113. An innate sense of danger
114. Is cancer dangerous to the immune system?
115. A theory of self-nonself discrimination
116. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction
117. The immune system evolved to discriminate infectious nonself from noninfectious self
118. The induction of tolerance by dendritic cells that have captured apoptotic cells
119. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
120. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
121. Tumor antigens recognized by T cells
122. Dendritic cells: Unique leukocyte populations which control the primary immune response
123. Dendritic cells and the control of immunity
124. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
125. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
126. Proliferating dendritic cell progenitors in human blood
127. Antigen capture, processing, and presentation by dendritic cells: Recent cell biological studies
128. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells
129. Natural adjuvants: Endogenous activators of dendritic cells
130. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
131. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
132. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
133. Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells
134. Role of dendritic cells in the immune response induced by mouse mammary tumor virus superantigen
135. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo
136. Dendritic cells induce immunity to cutaneous leishmaniasis in mice
137. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
138. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
139. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vice
140. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
141. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
142. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
143. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation
144. T-Cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor
145. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
146. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
147. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
148. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
149. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients
150. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
151. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer
152. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
153. Dendritic cell vaccines for cancer immunotherapy
154. Dendritic cell-based vaccine: A promising approach for cancer immunotherapy
155. Immunotherapy of cancer with dendritic-cell-based vaccines
156. Dendritic cell based therapy of cancer
157. Lnduction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
158. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
159. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
160. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells
161. Generation of dendritic cells from patients with chronic myelogenous leukemia
162. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
163. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
164. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
165. Gene-modified dendritic cells for use in tumor vaccines
166. Dendritic cells generated from peripheral blood transfected svith human tyrosinase induce specific T cell activation
167. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction
168. High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells
169. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
170. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
171. High efficiency adenovirus-mediated gene transfer to human dendritic cells
172. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
173. A comparison of gene transfer methods in human dendritic cells
174. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro
175. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
176. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
177. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity
178. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo
179. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
180. Poxyirus as a vector to transduce human dendritic cells for immunotherapy: Abortive infection but reduced APC function
181. Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity
182. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
183. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene
184. Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoietic progenitor-but not monocyte-derived dendritic cells
185. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing and IFN-alpha
186. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
187. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
188. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin
189. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells
190. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma
191. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
192. The central role of CD4(+) T cells in the antitumor immune response
193. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
194. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
195. Enhancement of antitumor immunity by CTLA-4 blockade
196. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer